The immunogenicity of therapeutic proteins

BioPharm

Volumn 15, Issue 2, 2002, Pages 30-36

  Adair, Fiona ^a   Ozanne, Daniel ^a  

^a MERCK KGAA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTIBODY; BACTERIAL ENZYME; BACTERIAL PROTEIN; BETA INTERFERON; BETA1A INTERFERON; BLOOD CLOTTING FACTOR 8; CONSENSUS INTERFERON; CYTOKINE; CYTOTOXIC AGENT; EPITOPE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; HLA DR ANTIGEN; IMMUNOTOXIN; INSULIN; INTERFERON BETA SERINE; LYSINE; MAJOR HISTOCOMPATIBILITY ANTIGEN; NEUTRALIZING ANTIBODY; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; RICIN; STAPHYLOKINASE; STREPTOKINASE; TOXIN; TRASTUZUMAB; UNINDEXED DRUG;

CANCER; CLINICAL TRIAL; DIABETES MELLITUS; DRUG HALF LIFE; HEMOPHILIA; HEPATITIS; HEPATITIS C; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; MULTIPLE SCLEROSIS; PREDICTION; RECOMBINANT DNA TECHNOLOGY; REVIEW;

EID: 0036162968     PISSN: 10408304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Clinical trials with blocked ricin immunotoxins
2. Immune tolerance induction in hemophilia patients with inhibitors: Costly can be cheaper
3. Interferon-Beta (INF-Beta) antibodies in Interferon-Beta 1 A- and Interferon-Beta 1 B-treated multiple sclerosis patients: Prevalence, kinetics, cross-reactivity, and factors enhancing Interferon-Beta immunogenicity in vivo
4. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function
5. On the immunogenicity of recombinant staphylokinase in patients and in animal models
6. A randomized, double-blind trial comparing PEGylated Interferon Alfa-2b to Interferon Alfa-2b as initial treatment for chronic hepatitis C
7. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity
8. Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection
9. Recombinant Factor VIIA for patients with inhibitors to Factor VIII or IX or Factor VII Deficiency
10. The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: The North American Registry, Factor VIII/IX subcommittee of the International Society for Thrombosis and Hemostasis
11. Immune tolerance in hemophilia: Principal results from the International Registry Report of the Factor VIII and IX subcommittee
12. Human major histocompatibility complex class II-associated invariant chain gene promoter: Functional analysis and in vivo protein-DNA interactions of constitutive and IFN-gamma-induced expression
13. Identification of a motif for HLA-DRI binding peptides using M13 display libraries
14. New methods to predict MHC-binding sequences within protein antigens
15. A comparison of three Interferon Alfa-2b regimens for the long-term treatment of chronic Non-A, Non-B hepatitis: Multicenter Study Group